GlassScriptPhysician profile
Taylor Torosyan
NPI 1528644754
$1,236.48
in general payments reported to CMS, 2019-2025
15 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2024: $458 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.66 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $209.56 | 2024-2025 | Erleada, Rybrevant, Akeega |
| Aveo Pharmaceuticals, INC. | $206.71 | 2024-2025 | |
| Astellas Pharma US INC | $170.50 | 2024-2025 | Padcev |
| Caris Mpi, INC. | $141.66 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $112.87 | 2022 | |
| Exelixis INC. | $107.41 | 2024-2025 | Cabometyx |
| Gilead Sciences, INC. | $50.29 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $47.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $47.16 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $30.18 | 2024 | Krazati |
| Tersera Therapeutics LLC | $29.67 | 2024 | Zoladex |
| Astrazeneca Pharmaceuticals LP | $22.43 | 2024 | Imfinzi |
| Eisai INC. | $21.46 | 2024 | |
| Springworks Therapeutics, INC. | $19.86 | 2025 | Ogsiveo |
| Pfizer INC. | $19.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Torosyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.